Zentalis Pharmaceuticals, Inc. (ZNTL)
Automate Your Wheel Strategy on ZNTL
With Tiblio's Option Bot, you can configure your own wheel strategy including ZNTL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZNTL
- Rev/Share 0.3748
- Book/Share 4.121
- PB 0.2936
- Debt/Equity 0.1309
- CurrentRatio 6.9367
- ROIC -0.6339
- MktCap 87061799.0
- FreeCF/Share -2.1165
- PFCF -0.5739
- PE -0.3869
- Debt/Assets 0.1006
- DivYield 0
- ROE -0.6548
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously …
Read More
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 50,000 shares of the Company's common stock and 25,000 restricted stock units to one newly hired employee. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / NEW YORK, February 27, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Zentalis Pharmaceuticals, Inc. (ZNTL)
- IPO Date 2020-04-03
- Website https://zentalis.com
- Industry Biotechnology
- CEO Ms. Julie M. Eastland M.B.A.
- Employees 166